Breast cancer drug fulvestrant appears more effective in the presence of CK8 and CK18

March 14th, 2010 by Newspublichealth.com

Women’s responsiveness to the second-line breast cancer drug fulvestrant may depend on whether the cancer cells are expressing two key proteins, scientists report.

Posted in Pharmacology | No Comments »
« Effort aims to spike breast cancer with new approach
Computer system helps reduce adverse drug side effects and interactions in ICU patients »
You can skip to the end and leave a response. Pinging is currently not allowed.

Leave a Reply

Sorry, no posts matched your criteria.